{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-014234","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.062825+00:00","generated_at":"2026-05-19T16:55:47.523155+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Harrow licenses exclusive U.S. rights to BYQLOVI ophthalmic steroid from Formosa","bullets":["Upfront payment of $500,000 at first commercial sale; additional milestone payments and royalties on gross profits.","BYQLOVI is first new ophthalmic steroid class in over 15 years; FDA-approved for post-op inflammation/pain.","Expected launch in Q4 2025; U.S. market exceeds 7M annual ophthalmic surgeries.","Clinical data: 77-85% pain-free at Day 4; 1.4% elevated IOP; BID dosing 14 days without loading/maintenance.","Formulated with Formosa's proprietary APNT nanoparticle technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-014234","json":"https://secwatch.observer/filing/0001641172-25-014234.json","markdown":"https://secwatch.observer/filing/0001641172-25-014234.md","text":"https://secwatch.observer/filing/0001641172-25-014234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/0001641172-25-014234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T16:55:47.523155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}